Immune to Cancer: The CRI Blog
- 
   
   
        Special Issue of Science Devoted to Cancer ImmunotherapyCRI scientists review the state of cancer immunotherapy in the latest issue of Science magazine. 
- 
   
   
        What Ever Happened to Coley’s Toxins?Experts today agree that a 100-year-old therapy cured cancer in some cases. Why did it fall out… 
- 
   
   
        How the Oncogene Opened the Door for Targeted TherapyEpisode 2 of The Emperor of All Maladies focused on key 20th century discoveries that changed the… 
- 
   
   
        Beyond Magic Bullets: Helen Coley Nauts and the Battle for ImmunotherapyHow one woman who lacked a college degree took on the cancer establishment and changed the course… 
- 
   
   
        ‘Emperor of All Maladies’, Quotes That Make You ThinkThree quotes from night one of #CancerFilm that stopped Emily Helck in her tracks. 
- 
   
   
        A Run to Reach New HeightsEarlier this month, Team CRI runners ran the 2015 United Airlines Half Marathon in NYC. 
- 
   
   
        Whose Cancer Is It, Anyway?When navigating cancer with someone you love, does the experience belong to just one of you? 
- 
   
   
        Merck’s PD-1 Drug Outperforms Ipilimumab for Treatment of Advanced MelanomaData from a phase III trial indicate that Keytruda stands ready to become standard-of-care for advanced melanoma. 

Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.
